Skip to main content
. 2021 Feb 3;6(4):1099–1109. doi: 10.1016/j.ekir.2021.01.034

Figure 2.

Figure 2

Kaplan-Meier curves. (a) End-stage kidney disease was less prevalent in patients with complement-mediated thrombotic microangiopathy (C-TMA) and coexisting conditions who had been treated with eculizumab compared with untreated patients (log-rank test, P < 0.001). (b) TMA recurrence after kidney transplantation was common in patients with C-TMA and (c) linked to rare variants in complement genes (log-rank test, P < 0.05).